Skip to main content

Drug Interactions between diflunisal and macimorelin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

diflunisal macimorelin

Applies to: diflunisal and macimorelin

GENERALLY AVOID: Drugs that directly affect the pituitary secretion of growth hormone (e.g., somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors such as aspirin and nonsteroidal anti-inflammatory drugs) and drugs that may transiently elevate growth hormone levels (e.g., clonidine, levodopa, insulin) may impact the accuracy of the macimorelin diagnostic test.

MANAGEMENT: Concomitant use of macimorelin with drugs affecting growth hormone levels should generally be avoided. A sufficient washout period following discontinuation of these drugs is recommended prior to macimorelin administration.

References

  1. "Product Information. Macrilen (macimorelin)." Aeterna Zentaris (2018):

Switch to consumer interaction data

Drug and food interactions

Moderate

macimorelin food

Applies to: macimorelin

ADJUST DOSING INTERVAL: Food reduces the oral bioavailability of macimorelin. According to the product labeling, administration with a liquid meal decreased macimorelin peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 49%, respectively, compared to administration under fasting conditions (i.e., for at least 8 hours).

MANAGEMENT: Macimorelin should be administered after fasting for at least 8 hours.

References

  1. "Product Information. Macrilen (macimorelin)." Aeterna Zentaris (2018):

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.